Advanced Oncotherapy Stock Price, News & Analysis (LON:AVO)

GBX 61.90 +2.40 (+4.03 %)
(As of 02/22/2018 06:19 AM ET)
Previous CloseGBX 59.50
Today's RangeGBX 58.50 - GBX 62
52-Week RangeGBX 9.75 - GBX 65
Volume22,616 shs
Average Volume93,894 shs
Market Capitalization£53.61 million
P/E Ratio-386.88
Dividend YieldN/A
BetaN/A

About Advanced Oncotherapy (LON:AVO)

Advanced Oncotherapy logoAdvanced Oncotherapy Plc is focused on providing radiotherapy systems for cancer treatment through the use of a proton therapy technology. The Company is engaged in development and then building of the Linac Image Guided Hadron Technology (LIGHT) proton beam cancer therapy device and management of healthcare related property. The Company's segments include Development of Proton Therapy-UK; Development of Proton Therapy-Switzerland; Development of Proton Therapy-USA, and Healthcare-related properties-UK. Its LIGHT system uses accelerators, which is a series of modular units. This feature offers hospitals and centers to customize treatment plans based on a range of energies. The Company's Research and development/ADAM S.A. (R&D/ADAM) facility is located on the campus of European Council for Nuclear Research (CERN), Geneva, Switzerland, and a manufacturing plant, clinical research and clinician training facility in Syracuse, the United States.

Receive AVO News and Ratings via Email

Sign-up to receive the latest news and ratings for AVO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Advanced Medical Equipment & Technology
Sub-IndustryN/A
SectorHealthcare
SymbolLON:AVO
CUSIPN/A
Phone+44-20-36178728

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-386.875
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSGBX (0.16)
Net IncomeN/A
Net MarginsN/A
Return on Equity-43.18%
Return on Assets-35.03%

Miscellaneous

EmployeesN/A
Outstanding Shares80,940,000

Advanced Oncotherapy (LON:AVO) Frequently Asked Questions

What is Advanced Oncotherapy's stock symbol?

Advanced Oncotherapy trades on the London Stock Exchange (LON) under the ticker symbol "AVO."

Who are some of Advanced Oncotherapy's key competitors?

Who are Advanced Oncotherapy's key executives?

Advanced Oncotherapy's management team includes the folowing people:

  • Michael J. Sinclair, Executive Chairman of the Board (Age 73)
  • Nicolas Serandour, Chief Executive Officer, Executive Director
  • Sanjeev Pandya, Executive Vice President - Global Business Development, Executive Director (Age 48)
  • Richard Amos, Director of Medical Physics
  • Michel Baelen, Head of Regulatory Affairs
  • Gerardo DAuria, Technical Director
  • Michael R. Graham, Global Head of QMS and Product Realisation
  • Donatella Ungaro, ADAM Managing Director Based at CERN
  • Michael Bradfield, Non-Executive Director (Age 63)
  • Steve Myers, Non-Executive Director

How do I buy Advanced Oncotherapy stock?

Shares of Advanced Oncotherapy and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Advanced Oncotherapy's stock price today?

One share of Advanced Oncotherapy stock can currently be purchased for approximately GBX 61.90.

How big of a company is Advanced Oncotherapy?

Advanced Oncotherapy has a market capitalization of £53.61 million.

How can I contact Advanced Oncotherapy?

Advanced Oncotherapy's mailing address is Third Fl Clearwater HSE, 4-7 Manchester Street, LONDON, W1U 3AE, United Kingdom. The company can be reached via phone at +44-20-36178728.


MarketBeat Community Rating for Advanced Oncotherapy (AVO)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  112 (Vote Outperform)
Underperform Votes:  177 (Vote Underperform)
Total Votes:  289
MarketBeat's community ratings are surveys of what our community members think about Advanced Oncotherapy and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Advanced Oncotherapy (LON:AVO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.002.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A

Advanced Oncotherapy (LON:AVO) Consensus Price Target History

Price Target History for Advanced Oncotherapy (LON:AVO)

Advanced Oncotherapy (LON:AVO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
2/27/2017Beaufort SecuritiesDowngradeHoldView Rating Details
(Data available from 2/22/2016 forward)

Earnings

Earnings History for Advanced Oncotherapy (LON:AVO)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Advanced Oncotherapy (LON:AVO) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Advanced Oncotherapy (LON:AVO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Advanced Oncotherapy (LON AVO) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Advanced Oncotherapy (LON:AVO)

Advanced Oncotherapy (LON AVO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/11/2018Enrico Cipro VanniInsiderBuy40,000GBX 55£22,000
7/31/2017Enrico Cipro VanniInsiderBuy100,000GBX 18£18,000
5/15/2017Steve Myers OBEInsiderBuy400,000GBX 26£104,000
5/9/2017Christopher NuttingInsiderBuy202,500GBX 25£50,625
4/25/2017Michael J SinclairInsiderBuy200,000GBX 30£60,000
4/24/2017Enrico Cipro VanniInsiderBuy100,000GBX 27£27,000
4/12/2017Enrico Cipro VanniInsiderBuy100,000GBX 28£28,000
4/4/2017Enrico Cipro VanniInsiderBuy25,000GBX 29£7,250
4/3/2017Michael J SinclairInsiderBuy100,000GBX 28£28,000
1/3/2017Enrico Cipro VanniInsiderBuy25,000GBX 87£21,750
12/29/2016Enrico Cipro VanniInsiderBuy25,000GBX 66£16,500
12/22/2016Enrico Cipro VanniInsiderBuy25,000GBX 60£15,000
12/20/2016Enrico Cipro VanniInsiderBuy25,000GBX 55£13,750
12/19/2016Enrico Cipro VanniInsiderBuy25,000GBX 50£12,500
7/11/2016Bradfield ,MichaelInsiderBuy30,000GBX 135£40,500
7/8/2016Bradfield ,MichaelInsiderBuy10,000GBX 120£12,000
7/7/2016Bradfield ,MichaelInsiderBuy10,000GBX 112£11,200
7/6/2016Bradfield ,MichaelInsiderBuy50,000GBX 102£51,000
12/18/2015Bradfield ,MichaelInsiderBuy750,000GBX 7£52,500
12/17/2015Bradfield ,MichaelInsiderBuy1,000,000GBX 6£60,000
12/16/2015Bradfield ,MichaelInsiderBuy750,000GBX 6£45,000
7/20/2015Vanni ,Enrico CiproInsiderBuy1,000,000GBX 8£80,000
7/1/2015Sinclair,Michael JInsiderSell7,000,000GBX 0.08£5,600
6/5/2015Michael BradfieldInsiderBuy1,500,000GBX 9.81£147,150
2/4/2015Michael BradfieldInsiderBuy500,000GBX 4.10£20,500
(Data available from 1/1/2013 forward)

Headlines

Advanced Oncotherapy (LON AVO) News Headlines

Source:

SEC Filings

Advanced Oncotherapy (LON:AVO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Advanced Oncotherapy (LON AVO) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.